Rather than targeting the pathogen directly, Lu120819 modulates immune-metabolic imbalance and stress-associated host responses — a host-directed strategy spanning viral, bacterial, and fungal infections.
Lu120819 is being investigated for cardiovascular disease areas involving tissue injury, pathological remodeling, fibrosis, and mitochondrial dysfunction.
Lu120819 is being advanced as part of a preparedness-oriented development strategy for high-risk viral threats, including H5N1.
LUTERION is exploring Lu120819 across diseases in which mitochondrial dysfunction, immune dysregulation, and impaired recovery from cellular stress are biologically connected.